Xiaozhi formula improves lipid metabolism disorders in NALFD by inhibiting the lipid synthesis pathway (Srebp-1c/Fasn) and activating the fatty acid β-oxidation pathway (Ppar-α/Cpt-1) (You et al., 2024). Here, PPARA is linked to Disorder of lipid metabolism.